S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
Log in
NASDAQ:BCLI

Brainstorm Cell Therapeutics Short Interest Ratio and Short Volume

$3.99
-0.16 (-3.86 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.97
Now: $3.99
$4.25
50-Day Range
$3.97
MA: $5.88
$7.88
52-Week Range
$3.80
Now: $3.99
$17.95
Volume538,367 shs
Average Volume1.21 million shs
Market Capitalization$142.53 million
P/E RatioN/A
Dividend YieldN/A
Beta0.37

Short Interest

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Short Interest Data

Current Short Volume4,220,000 shares
Previous Short Volume4,660,000 shares
Change Vs. Previous Month:-9.44%
Dollar Volume Sold Short$17.13 million
Short Interest Ratio / Days to Cover3.2
Last Record DateFebruary, 12 2021
Outstanding Shares21,700,000 shares
Percentage of Shares Shorted11.81%
Today's Trading Volume538,367 shares
Average Trading Volume1,210,190 shares
Today's Volume Vs. Average-55.51%

Short Interest Over Time


Brainstorm Cell Therapeutics (NASDAQ:BCLI) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
2/12/20214,220,000 shares $17.13 million -9.4%N/A3.2 $4.06
1/29/20214,660,000 shares $33.65 million -2.9%N/A3.1 $7.22
1/15/20214,800,000 shares $30.29 million -11.1%N/A3.6 $6.31
12/31/20206,370,000 shares $29.49 million -5.9%N/A4.9 $4.63
12/15/20206,370,000 shares $29.62 million -5.9%N/A4.9 $4.65
11/30/20206,770,000 shares $36.02 million +5.5%N/A5.7 $5.32
11/15/20206,420,000 shares $35.50 million +7.5%N/A6.1 $5.53
10/30/20205,970,000 shares $69.55 million +17.5%N/A10.2 $11.65
10/15/20205,080,000 shares $53.64 million +12.1%N/A8.4 $10.56
9/30/20204,530,000 shares $76.78 million +18.3%N/A8.7 $16.95
9/15/20203,830,000 shares $57.26 million -1.5%N/A6 $14.95
8/31/20203,890,000 shares $53.99 million +8.1%N/A5.5 $13.88
8/14/20203,600,000 shares $44.17 million +2.9%N/A4.8 $12.27
7/31/20203,500,000 shares $50.19 million -20.8%N/A4.8 $14.34
7/15/20204,420,000 shares $59.89 million No ChangeN/A6.3 $13.55
6/30/20204,420,000 shares $68.91 million +39.9%N/A7 $15.59
6/15/20203,160,000 shares $35.90 million +12.1%N/A5.8 $11.36
5/29/20202,820,000 shares $29.22 million -4.4%N/A5.2 $10.36
5/15/20202,950,000 shares $21.98 million +12.2%N/A4.7 $7.45
4/30/20202,630,000 shares $17.44 million +14.9%N/A3.2 $6.63
4/15/20202,290,000 shares $13.42 million +22.5%10.8%3 $5.86
3/31/20201,870,000 shares $11.35 million +69.5%8.8%2.6 $6.07
3/13/20201,103,400 shares $5.62 million +3.1%5.9%1.9 $5.09
2/28/20201,070,000 shares $4.94 million +40.8%5.8%2 $4.62
2/14/2020759,900 shares $5.65 million +4.8%4.1%1.7 $7.44

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Short Interest FAQ

speech bubbles
speech bubbles











What is Brainstorm Cell Therapeutics' current short interest?

Short interest is the volume of Brainstorm Cell Therapeutics shares that have been sold short but have not yet been closed out or covered. As of February 12th, investors have sold 4,220,000 shares of BCLI short.

What is a good short interest ratio for Brainstorm Cell Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Brainstorm Cell Therapeutics currently has a short interest ratio of 3.0.

Is Brainstorm Cell Therapeutics' short interest increasing or decreasing?

Brainstorm Cell Therapeutics saw a decrease in short interest during the month of February. As of February 12th, there was short interest totaling 4,220,000 shares, a decrease of 9.4% from the previous total of 4,660,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Brainstorm Cell Therapeutics' short interest compare to its competitors?

0.00% of Brainstorm Cell Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Brainstorm Cell Therapeutics: Gritstone Oncology, Inc. (8.43%), MeiraGTx Holdings plc (1.22%), Oyster Point Pharma, Inc. (9.29%), Harpoon Therapeutics, Inc. (2.94%), Jounce Therapeutics, Inc. (6.38%), Fusion Pharmaceuticals Inc. (1.62%), Opthea Limited (0.00%), AVROBIO, Inc. (0.00%), Cardiff Oncology, Inc. (18.60%), and Codiak BioSciences, Inc. (3.24%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: ViacomCBS Inc. ($6.50 billion), Aon Plc ($5.58 billion), Charter Communications, Inc. ($5.30 billion), Analog Devices, Inc. ($4.97 billion), Snap Inc. ($3.80 billion), Futu Holdings Limited ($2.84 billion), Airbnb, Inc. ($2.40 billion), Discovery, Inc. ($2.35 billion), Snowflake Inc. ($2.07 billion), and The Kroger Co. ($2.00 billion). View all of the most shorted stocks.

What does it mean to sell short Brainstorm Cell Therapeutics stock?

Short selling BCLI is an investing strategy that aims to generate trading profit from Brainstorm Cell Therapeutics as its price is falling. Brainstorm Cell Therapeutics' stock is trading down $0.16 today. To short Brainstorm Cell Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Brainstorm Cell Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Brainstorm Cell Therapeutics?

A short squeeze for Brainstorm Cell Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BCLI, which in turn drives the price of the stock up even further.

How often is Brainstorm Cell Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCLI, twice per month. The most recent reporting period available is February, 12 2021.



This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.